

GSK makes a strong start to 2024 with improving outlook for the year

“We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”

Emma Walmsley
Chief Executive Officer, GSK



Vaccines
£2.3bn
+16%, +22%
including and excluding COVID-19 solutions

Specialty Medicines
£2.5bn
+17%, +19%
including and excluding COVID-19 solutions, with HIV +14%

General Medicines
£2.6bn
+1%

Core operating profit
£2.4bn
+27%, +35% including and excluding COVID-19 solutions

Total EPS
25.7p -19%

Core EPS
43.1p
+28%, +37% including and excluding COVID-19 solutions

Dividend
15p

72
vaccines and medicines in pipeline

4
positive data read outs on phase III medicines

Journalists/media see press release on www.gsk.com for full details on Q1 2024.
Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on page 49 of the press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER).